Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

An Ex Vivo Human Liver Model for Lentiviral Vector Profiling
40:21

From Aspiring Astronaut to CAR-T Pioneer: A Journey of Serendipity with Bruce Levine, PhD
47:50

Advancements in Pediatric Cancer Therapy with Nirali Shah and Timothy Cripe
32:17